Drug intelligence / Profile preview

PANVAC-VF

Development stage: Phase 3
Lead developer: Therion Biologics
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intradermal

Overview

PANVAC-VF is a biological intervention developed by Therion Biologics Corporation. It is being evaluated in a Phase III clinical trial for the treatment of metastatic (Stage IV) adenocarcinoma of the pancreas in patients who have failed a gemcitabine-containing chemotherapy regimen. The name suggests it is a vaccine for pancreatic cancer.

Other names: PANVAC™-VF

Beyond the preview

Go deeper on PANVAC-VF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PANVAC-VF.

Explore the full profile